Roger Faroux

7.7k total citations · 1 hit paper
98 papers, 2.5k citations indexed

About

Roger Faroux is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Roger Faroux has authored 98 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 20 papers in Hepatology. Recurrent topics in Roger Faroux's work include Colorectal Cancer Treatments and Studies (56 papers), Gastric Cancer Management and Outcomes (23 papers) and Cancer Treatment and Pharmacology (21 papers). Roger Faroux is often cited by papers focused on Colorectal Cancer Treatments and Studies (56 papers), Gastric Cancer Management and Outcomes (23 papers) and Cancer Treatment and Pharmacology (21 papers). Roger Faroux collaborates with scholars based in France, Belgium and Switzerland. Roger Faroux's co-authors include Michel Ducreux, Gérard Lledo, Julien Taı̈eb, Pascal Hammel, Christophe Louvet, Thierry André, Aimery de Gramont, Céline Lepère, Enrico Aitini and Maria Giulia Zampino and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and Journal of Hepatology.

In The Last Decade

Roger Faroux

95 papers receiving 2.4k citations

Hit Papers

Gemcitabine in Combination With Oxaliplatin Compared With... 2005 2026 2012 2019 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
    2005 760 citations Christophe Louvet, Roberto Labianca et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roger Faroux France 23 1.7k 684 599 550 452 98 2.5k
Thomas A. Abrams United States 25 1.4k 0.8× 668 1.0× 655 1.1× 354 0.6× 306 0.7× 84 2.4k
Benoist Chibaudel France 28 2.9k 1.7× 1.3k 1.9× 1.0k 1.7× 724 1.3× 359 0.8× 157 3.7k
Matias Riihimäki Sweden 12 1.4k 0.8× 821 1.2× 460 0.8× 295 0.5× 378 0.8× 12 2.2k
Pascal Artru France 28 3.1k 1.8× 1.4k 2.1× 854 1.4× 979 1.8× 569 1.3× 132 3.7k
Xavier Bessa Spain 28 1.7k 1.0× 615 0.9× 545 0.9× 432 0.8× 337 0.7× 93 2.5k
Renuka Iyer United States 31 1.5k 0.8× 753 1.1× 755 1.3× 460 0.8× 501 1.1× 178 3.0k
Shinichi Ohkawa Japan 24 1.2k 0.7× 648 0.9× 631 1.1× 410 0.7× 697 1.5× 96 2.3k
Sylvain Manfrédi France 28 2.3k 1.3× 1.2k 1.8× 1.3k 2.1× 446 0.8× 369 0.8× 117 3.5k
Heinz‐Josef Klümpen Netherlands 30 1.6k 0.9× 983 1.4× 1.2k 2.0× 408 0.7× 903 2.0× 154 3.3k
Walid L. Shaib United States 25 1.4k 0.8× 472 0.7× 964 1.6× 331 0.6× 319 0.7× 129 2.5k

Countries citing papers authored by Roger Faroux

Since Specialization
Citations

This map shows the geographic impact of Roger Faroux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Faroux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Faroux more than expected).

Fields of papers citing papers by Roger Faroux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Faroux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Faroux. The network helps show where Roger Faroux may publish in the future.

Co-authorship network of co-authors of Roger Faroux

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Faroux. A scholar is included among the top collaborators of Roger Faroux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Faroux. Roger Faroux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gelu‐Siméon, Moana, et al.. (2022). The Characteristics of Diverticular Disease in Caribbean Population: A Control Group Study. Canadian Journal of Gastroenterology and Hepatology. 2022. 1–9. 2 indexed citations
2.
Lepage, Côme, Jean–Marc Phelip, Laurent Cany, et al.. (2020). 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial. Annals of Oncology. 31. S410–S410. 5 indexed citations
3.
Aparicio, Thomas, Jaafar Bennouna, Karine Le Malicot, et al.. (2020). Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. British Journal of Cancer. 122(7). 957–962. 4 indexed citations
4.
Gallois, Claire, Pascal Artru, Astrid Lièvre, et al.. (2019). Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. European Journal of Cancer. 119. 35–43. 28 indexed citations
5.
6.
Jouve, Jean–Louis, Thierry Lecomte, Olivier Bouché, et al.. (2019). Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. Journal of Hepatology. 71(3). 516–522. 82 indexed citations
7.
Randrian, Violaine, Antoine Adenis, Jérôme Desrame, et al.. (2019). Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and Liver Disease. 52(3). 347–350. 3 indexed citations
8.
Hammel, Pascal, Jean‐Baptiste Bachet, Iman El‐Hariry, et al.. (2017). A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).. Journal of Clinical Oncology. 35(15_suppl). e15718–e15718. 5 indexed citations
9.
Aparicio, Thomas, Olivier Bouché, Julien Taı̈eb, et al.. (2017). Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results. Annals of Oncology. 29(1). 133–138. 50 indexed citations
10.
Lepage, Côme, Laurent Cany, E. Maillard, et al.. (2016). Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology. 27. vi159–vi159. 3 indexed citations
11.
Aparicio, Thomas, O. Bouché, Éric François, et al.. (2016). Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. Annals of Oncology. 27. vi194–vi194. 1 indexed citations
12.
Aparicio, Thomas, E. Maillard, Michel Ducreux, et al.. (2016). Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.. Journal of Clinical Oncology. 34(15_suppl). 3532–3532. 1 indexed citations
13.
Boige, Valérie, Marc Vincent, Jan Stoehlmacher, et al.. (2015). DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 3584–3584. 1 indexed citations
14.
Metges, Jean‐Philippe, Roger Faroux, Jean-Yves Douillard, et al.. (2013). Efficacy and safety of FOLFIRINOX in patients with pancreatic metastatic cancer.. Journal of Clinical Oncology. 31(4_suppl). 248–248. 1 indexed citations
15.
Nahon, Stéphane, Hervé Hagège, Jean‐Paul Latrive, et al.. (2012). Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy. 44(11). 998–1008. 67 indexed citations
16.
Bennouna, Jaafar, Christophe Borg, Jean‐Pierre Delord, et al.. (2011). Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer. 11(1). 38–44. 26 indexed citations
17.
Étienne-Grimaldi, Marie-Christine, Jaafar Bennouna, M Francoual, et al.. (2011). Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5‐fluorouracil‐based therapy together with cetuximab–irinotecan. British Journal of Clinical Pharmacology. 73(5). 776–785. 32 indexed citations
18.
Tournoux‐Facon, Caroline, Xavier Paolettí, Jean‐Claude Barbare, et al.. (2010). Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. Journal of Hepatology. 54(1). 108–114. 22 indexed citations
19.
Küry, Sébastien, Bruno Buecher, Sébastien Robiou-du-Pont, et al.. (2007). The Thorough Screening of the MUTYH Gene in a Large French Cohort of Sporadic Colorectal Cancers. Genetic Testing. 11(4). 373–380. 12 indexed citations
20.
Louvet, Christophe, Roberto Labianca, Pascal Hammel, et al.. (2005). Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. Journal of Clinical Oncology. 23(15). 3509–3516. 760 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas A. Abrams Breakdown of academic impact, for papers by Benoist Chibaudel Breakdown of academic impact, for papers by Matias Riihimäki Breakdown of academic impact, for papers by Pascal Artru Breakdown of academic impact, for papers by Xavier Bessa Breakdown of academic impact, for papers by Renuka Iyer Breakdown of academic impact, for papers by Shinichi Ohkawa Breakdown of academic impact, for papers by Sylvain Manfrédi Breakdown of academic impact, for papers by Heinz‐Josef Klümpen Breakdown of academic impact, for papers by Walid L. Shaib
Rankless by CCL
2026